The proposed changes to the Medicare Shared Savings Program that move accountable care organizations (ACOs) to take on risk in just 2 years is not going to be enough time for most ACOs, although some may be ready in that time, said Stephen Nuckolls, CEO of Coastal Carolina Quality Care.
The proposed changes to the Medicare Shared Savings Program that move accountable care organizations (ACOs) to take on risk in just 2 years is not going to be enough time for most ACOs, although some may be ready in that time, said Stephen Nuckolls, CEO of Coastal Carolina Quality Care.
Transcript
Previous research has shown that ACOs that are doing it longer, perform better. Do you think the shorter 2-year timeline to take on risk provides enough time for ACOs to figure it out?
[CMS has] drastically shortened the time period from 6 years to 2 years. I know for our ACO, we did not achieve savings in the first 3-year contract period, and if we had been then required to take on risk after 2 years after just seeing just the first year’s results, I don’t think our ACO would still be an ACO. We would have dropped out of the program.
I don’t believe that’s enough time. And I think we were able to move a lot more quickly as a small ACO than some of the larger systems. I think ACOs are going to need more time to get ready for risk.
Some may be ready in that period of time, but there are many different things that go on with how you formulate the benchmark and how the benchmark impacts local markets, and it’s less about being ready for risk and knowing what the risks are, evaluating the risks to see what your odds of success are and what the probabilities are.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More